Management and Predictors of Treatment Failure in Patients with Chemo-Resistant/Relapsed Gestational Trophoblastic Neoplasia with Lung Metastasis

The aim of the study was to assess the effectiveness of a combined treatment modality of salvage chemotherapy and pulmonary resection in chemo-resistant/relapsed gestational trophoblastic neoplasia (GTN) with lung metastasis and identify predictors of treatment failure. Data of patients with chemo-resistant/relapsed GTN with lung metastasis who received salvage chemotherapy combined with pulmonary resection were retrospectively analyzed. Among 134 included patients, the number of preoperative chemotherapy regimens ranged from 2–8 (median, 3), and courses ranged from 4–37 (median, 14). Pulmonary lobectomies, segmentectomies, wedge resections, and lobectomies plus wedge resections were performed in 84, 5, 35, and 10 patients, respectively. After completion of treatment, 130 (97.0%) patients achieved complete remission. In the entire cohort, the 5-year overall survival (OS) rate was 87.6%. OS rates were similar between stage III and stage IV disease cohorts (89.4% vs. 75.0%, p = 0.137). Preoperative β-human chorionic gonadotropin (β-hCG) levels > 10 IU/L (p = 0.027) and number of preoperative chemotherapy regimens > 3 (p = 0.018) were predictors of treatment failure. The combined treatment modality of salvage chemotherapy and pulmonary resection is effective in patients with chemo-resistant/relapsed GTN with lung metastasis, improving their prognoses. Patients with preoperative serum β-hCG >10 IU/L and those with >3 chemotherapy regimens preoperatively may not benefit from this multidisciplinary treatment.

[1]  M. Candiani,et al.  Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN) , 2022, Cancers.

[2]  Jun Zhao,et al.  Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. , 2021, The Lancet. Oncology.

[3]  N. Horowitz,et al.  Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. , 2021, Gynecologic oncology.

[4]  R. Berkowitz,et al.  Diagnosis and management of gestational trophoblastic disease: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[5]  R. Berkowitz,et al.  Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. , 2021, Best practice & research. Clinical obstetrics & gynaecology.

[6]  H. Ngan,et al.  Surgery including fertility-sparing treatment of GTD , 2020, Best Practice & Research Clinical Obstetrics & Gynaecology.

[7]  M. Seckl,et al.  Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma: a UK population study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[8]  R. Berkowitz,et al.  Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  A. Akarca,et al.  Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia , 2017, The Lancet.

[10]  R. Berkowitz,et al.  Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. , 2017, Gynecologic oncology.

[11]  M. Kanis,et al.  Pulmonary Resection in the Management of High-Risk Gestational Trophoblastic Neoplasia , 2016, International Journal of Gynecologic Cancer.

[12]  F. Sweep,et al.  Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. , 2016, Gynecologic oncology.

[13]  Young Tae Kim,et al.  Role of surgical therapy in the management of gestational trophoblastic neoplasia , 2015, Obstetrics & gynecology science.

[14]  T. Lawrie,et al.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. , 2012, The Cochrane database of systematic reviews.

[15]  Y. Xiang,et al.  Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Lurain Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. , 2011, American journal of obstetrics and gynecology.

[17]  J. Lurain Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. , 2010, American journal of obstetrics and gynecology.

[18]  Neil J Sebire,et al.  Gestational trophoblastic disease , 2010, The Lancet.

[19]  R. Hanna,et al.  The role of surgery and radiation therapy in the management of gestational trophoblastic disease. , 2010, The oncologist.

[20]  Y. Xiang,et al.  Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia. , 2009, Gynecologic oncology.

[21]  Y. Xiang,et al.  Surgical Resection in the Management of Pulmonary Metastatic Disease of Gestational Trophoblastic Neoplasia , 2009, International Journal of Gynecologic Cancer.

[22]  N. Sebire,et al.  Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Berkowitz,et al.  The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. , 2008, The Journal of reproductive medicine.

[24]  T. Powles,et al.  A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia , 2007, British Journal of Cancer.

[25]  S. Akiyama,et al.  Operative procedure and indications for surgical management of pulmonary metastasis of choriocarcinoma , 2006, The Japanese journal of surgery.

[26]  J. Soper Role of surgery and radiation therapy in the management of gestational trophoblastic disease. , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[27]  H. Smith Gestational trophoblastic disease epidemiology and trends. , 2003, Clinical obstetrics and gynecology.

[28]  M. Seckl,et al.  Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E S Newlands,et al.  EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Mutch,et al.  Recurrent gestational trophoblastic disease. Experience of the southeastern regional trophoblastic disease center , 1990, Cancer.

[31]  E. Surwit,et al.  Recurrent gestational trophoblastic disease. , 1981, Gynecologic oncology.

[32]  Y. Tomoda,et al.  Surgical indications for resection in pulmonary metastasis of choriocarcinoma , 1980, Cancer.